Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cipher Pharmaceuticals ( (TSE:CPH) ) has issued an update.
Cipher Pharmaceuticals reported significant financial growth in the third quarter of 2025, with a 24% increase in total revenue to $12.8 million and a 79% rise in adjusted EBITDA to $7.3 million compared to the same period in 2024. The company has made substantial progress in reducing its debt, with $32 million in repayments over the past six months, positioning itself well for future growth opportunities. The passing of a key board member, Harold M. Wolkin, was also noted, highlighting his contributions to the company’s strategic initiatives.
The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$16.50 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.
Spark’s Take on TSE:CPH Stock
According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.
Cipher Pharmaceuticals’ strong financial performance and record-breaking earnings in Q2 2025 are significant positives. The company’s strategic initiatives, including debt reduction and share repurchases, further enhance its growth prospects. However, challenges in profitability sustainability and bearish technical indicators moderate the overall outlook.
To see Spark’s full report on TSE:CPH stock, click here.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology products. The company is known for its product Natroba™, which is a key contributor to its revenue growth.
Average Trading Volume: 26,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$375.6M
For a thorough assessment of CPH stock, go to TipRanks’ Stock Analysis page.